2 February 2022 - Novo Nordisk on Wednesday rejected allegations by a U.S. congressional investigative committee that it has engaged in manoeuvres to increase net prices on life-saving insulin in tandem with its competitors on the U.S. insulin market.

The report, released in December by the House Oversight Committee, the main investigative body of the U.S. House of Representatives, alleged Novo had increased prices on its insulin drugs to the detriment of diabetes patients between 2001 and 2019.

Read Reuters article